drugset / Trial / NCT06412198
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To learn if the drug combination of adagrasib, cetuximab, and cemiplimab can help to control metastatic CRC with KRAS G12C mutations.
Timeline
- Start
- 2024-08-28
- Primary completion
- 2029-03-01
- Completion
- 2029-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adagrasib | Small molecule | — | Oral |
| Subject | Cemiplimab | Monoclonal antibody | — | Intravenous |
| Subject | Cetuximab | Monoclonal antibody | — | Intravenous |